Background Unlike most chronic diseases, osteoporosis treatments are generally limited to
a single drug at a fixed dose and frequency. Nonetheless, no approved therapy is able to …

Background Osteoporosis medications increase bone-mineral density (BMD) and lower but
do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has …

Summary Background In the Denosumab and Teriparatide Administration (DATA) study, we
showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing …

Context: Current osteoporosis medications increase bone mineral density (BMD) modestly
and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering …

When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly
decreases. To compare rates of bone loss in postmenopausal women who discontinue …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

The FREEDOM study and its Extension provide long-term information about the effects of
denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years …

Studies examining real-world effectiveness of osteoporosis therapies are beset by
limitations due to confounding by indication. By evaluating longitudinal changes in fracture …

The 3‐year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6
months for the treatment of postmenopausal women with osteoporosis. Participants who …

Context: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months
(FREEDOM) extension is evaluating the long-term efficacy and safety of denosumab for up …